Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 7/20 | 0.35 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.35 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.34 |
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31276569 | 1.00 | GCK (0.40) | GCKGRM2RIPK2UHRF1PLA2G7 | |
| SCHEMBL17460302 | 1.00 | GCK (0.40) | GCKGRM2RIPK2UHRF1PLA2G7 | |
| SCHEMBL17460299 | 0.91 | HSD17B10 (0.38) | GCKGRM2RIPK2THRBRORC | |
| SCHEMBL17460267 | 0.87 | GRM2 (0.39) | GCKGRM2 | |
| SCHEMBL15901323 | 0.85 | GCK (0.39) | GCKRIPK2RECQLTHRBRORC | |
| SCHEMBL29918291 | 0.83 | GRM2 (0.45) | GCKGRM2P2RX3 | |
| SCHEMBL19767022 | 0.83 | GRM2 (0.45) | GCKGRM2P2RX3 | |
| SCHEMBL21158230 | 0.83 | UHRF1 (0.44) | GCKGRM2RIPK2UHRF1DYRK1A | |
| SCHEMBL15900902 | 0.82 | RECQL (0.51) | GCKRIPK2PLA2G7RECQLTHRB | |
| SCHEMBL29918331 | 0.82 | RECQL (0.51) | GCKRIPK2PLA2G7RECQLTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119161343-A | Bridged pyrimidinone compounds, preparation method thereof, pharmaceutical composition and application thereof | 上海深势唯思科技有限责任公司 | 2024-12-20 | — | — | CN | disclosed |
| CN-119143780-A | Lp-PLA2 inhibitor, preparation method thereof, pharmaceutical composition and application thereof | 上海深势唯思科技有限责任公司 | 2024-12-17 | — | — | CN | disclosed |
| US-20240246995-A1 | PYRIMIDINONE DERIVATIVE AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2024-07-25 | — | — | US | disclosed |
| EP-4324835-A1 | PYRIMIDINONE DERIVATIVE AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2024-02-21 | — | — | EP | disclosed |
| CN-113861220-B | Tricyclic pyrimidinone compounds, methods of making, compositions and uses thereof | 上海纽思克生物科技有限公司 | 2023-06-16 | — | — | CN | disclosed |
| US-20230044787-A1 | TRICYCLE DIHYDROIMIDAZOPYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI SIMRD BIOTECHNOLOGY CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| EP-4056571-A1 | TRICYCLIC DIHYDROIMIDAZOPYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2022-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246995-A1 | PYRIMIDINONE DERIVATIVE AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE | PLA2G1B, LYPLAL1, PLA2G12B | GCK 1230/4885GRM2 2088/4885RIPK2 3243/4885 |
| US-20230044787-A1 | TRICYCLE DIHYDROIMIDAZOPYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | LYPLAL1, LYPLA1, LYPLA2 | GCK 1158/4885GRM2 4191/4885RIPK2 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.